Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| MDA-MB-157 | MK 1775 | 0.001 | 1.1776 | -0.00242 |
| HCC1395 | AZD6738 | 0.00316227766017 | 1.1776 | -0.01715 |
| MDA-MB-453 | AZD6738 | 0.01 | 1.1777 | -0.00168 |
| MDA-MB-436 | AZD5363 | 0.001 | 1.1778 | -0.00370 |
| SK-BR-3 | MK 1775 | 0.001 | 1.1779 | -0.00498 |
| T47D | THZ531 | 0.01 | 1.1780 | -0.00471 |
| CAMA-1 | MK 1775 | 0.001 | 1.1782 | 0.00176 |
| MDA-MB-436 | RO-3306 | 1.0 | 1.1784 | 0.01039 |
| MDA-MB-134-VI | Ulixertinib | 0.001 | 1.1784 | -0.03199 |
| HCC1954 | AZD6738 | 0.316227766 | 1.1785 | -0.00726 |
| CAMA-1 | Rucaparib | 0.001 | 1.1788 | -0.00306 |
| MDA-MB-361 | Senexin B | 0.01 | 1.1788 | -0.00708 |
| AU565 | AZD6738 | 0.031622777 | 1.1789 | 0.00739 |
| MDA-MB-436 | THZ531 | 0.0001 | 1.1791 | -0.01967 |
| MDA-MB-157 | Alvocidib | 0.000316227766017 | 1.1795 | -0.03277 |
| SK-BR-3 | RO-3306 | 0.001 | 1.1798 | 0.00853 |
| MDA-MB-361 | Ulixertinib | 0.1 | 1.1802 | -0.01683 |
| SK-BR-3 | AZD6738 | 0.001 | 1.1802 | -0.01261 |
| SUM1315MO2 | THZ1 | 0.031622777 | 1.1804 | -0.02501 |
| HCC70 | SHP099 | 0.001 | 1.1814 | 0.00289 |
| SK-BR-3 | Rucaparib | 0.001 | 1.1820 | -0.00714 |
| CAL-120 | AZD6738 | 0.001 | 1.1827 | -0.00059 |
| MDA-MB-468 | Alvocidib | 0.0001 | 1.1827 | -0.01803 |
| MDA-MB-134-VI | Ulixertinib | 0.1 | 1.1829 | -0.03610 |
| HCC1954 | AZD6738 | 0.01 | 1.1834 | -0.00148 |